Head-to-head · Cost-Efficiency Index
Evernow vs VyrarX
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Evernow
Cost-first shoppers who want women 40+ wanting GLP-1 prescribing integrated with menopause/hormone care, ideally with insurance.
Visit EvernowVyrarX
Shoppers comparing headline GLP-1 starting prices who don't need pharmacy/clinical-leadership transparency up front.
Visit VyrarXThe verdict
Evernow and VyrarX tie on the Cost-Efficiency Index at 49/100, so neither wins outright on the numbers. For most shoppers we'd start with Evernow (ranked #421, a hair above #428) — Cost-first shoppers who want women 40+ wanting GLP-1 prescribing integrated with menopause/hormone care, ideally with insurance. But VyrarX is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Evernow.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Evernow | VyrarX |
|---|---|---|
| Cost-Efficiency Index | 49/100 | 49/100 |
| Semaglutide / mo | Not disclosed | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | — | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #421 | #428 |
Evernow
49/100Where the value is
- Confirmed genuine GLP-1 prescribing (not hormone-therapy-only, despite the brand's menopause focus)
- Only prescribes FDA-approved branded medications, no compounded-drug quality uncertainty
- Available in all 50 states plus D.C.
The tradeoffs
- No cash-pay price published anywhere -- cost is insurance-dependent and opaque to uninsured shoppers
- No compounded option for patients priced out of branded GLP-1s
VyrarX
49/100Where the value is
- Clear headline pricing for both semaglutide and tirzepatide
- Claims broad 47-state coverage
- LegitScript seal displayed on the homepage
The tradeoffs
- No named medical director or clinical leadership anywhere on the public site
- No named compounding pharmacy partner disclosed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.